Navelbine (Vinorelbine Tartrate)

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as an intravenous solution for intravenous use. It is employed in the treatment of certain solid tumours, notably non‑small cell lung cancer and metastatic breast cancer, and is administered under the supervision of oncology specialists.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance while providing reliable global distribution.

Vinorelbine is a Vinca alkaloid used in chemotherapy for solid tumours.

- Non‑small cell lung cancer: improves disease control and may extend survival in patients with advanced disease. - Metastatic breast cancer: used after failure of anthracycline‑based therapy to reduce tumour burden. - Solid tumours (in combination regimens): contributes to cytotoxic activity when combined with other chemotherapeutic agents.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: gastrointestinal upset common during treatment. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss that may be temporary.

Serious or Rare Side Effects: - Severe neutropenia with fever: requires immediate medical attention. - Pulmonary toxicity: cough, dyspnoea, or interstitial pneumonitis. - Hypersensitivity reactions: rash, flushing, or anaphylaxis. - Peripheral neuropathy: tingling or numbness in extremities. - Cardiac toxicity: arrhythmias or decreased cardiac function.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity.

- Monitor blood counts: perform regular CBC to detect neutropenia and thrombocytopenia. - Assess liver function: adjust therapy if hepatic impairment is present. - Evaluate pulmonary status: baseline and periodic lung function tests are recommended. - Use antiemetics prophylactically: to mitigate nausea and vomiting. - Store at ambient temperature: keep in original container, protect from light and moisture.

Vinorelbine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinorelbine exposure and toxicity. - Concurrent myelosuppressive agents: exacerbate bone‑marrow suppression. - Radiotherapy to the chest: may heighten risk of pulmonary toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduce vinorelbine plasma levels. - Anticoagulants (e.g., warfarin): may increase bleeding tendency. - Other anti‑emetics (e.g., ondansetron): can affect drug metabolism. - Herbal supplements (e.g., St John's wort): may alter vinorelbine clearance.